Skip to content

NIKA PHARMACEUTICALS, INC.: 10-Q/A filed 2024-11-01

What NIKA PHARMACEUTICALS, INC. reported in its quarterly report amendment filed 2024-11-01 (fiscal Q2 2024): 28 published measures, 79 facts as tagged in accession 0001826466-24-000136.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2024-11-01
Fiscal period
fiscal Q2 2024
Accession
0001826466-24-000136 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NIKA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-30390,323USD
At 2023-12-3119,596USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-30636,934USD
At 2023-12-31101,745USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-246,611USD
At 2024-03-31-225,482USD
At 2023-12-31-82,149USD
At 2023-06-30-64,692USD
At 2023-03-31-36,886USD
At 2022-12-31-17,316USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-06-307,486USD
At 2023-12-3119,596USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-54,800USD91
2024-01-01 to 2024-06-30-114,025USD182
2023-04-01 to 2023-06-30-27,806USD91
2023-01-01 to 2023-06-30-47,376USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-523,066USD182
2023-01-01 to 2023-06-30-47,376USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-30530,552USD182
2023-01-01 to 2023-06-3057,565USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-8,956,004USD
At 2023-12-31-3,400,247USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,018,519,500shares91
2024-01-01 to 2024-06-301,018,519,500shares182
2023-04-01 to 2023-06-30876,090,000shares91
2023-01-01 to 2023-06-30876,090,000shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,018,519,500shares91
2024-01-01 to 2024-06-301,018,519,500shares182
2023-04-01 to 2023-06-30876,090,000shares91
2023-01-01 to 2023-06-30876,090,000shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182
2023-04-01 to 2023-06-300USD/shares91
2023-01-01 to 2023-06-300USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182
2023-04-01 to 2023-06-300USD/shares91
2023-01-01 to 2023-06-300USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-06-30168,259USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-54,800USD91
2024-01-01 to 2024-06-30-114,025USD182
2023-04-01 to 2023-06-30-27,806USD91
2023-01-01 to 2023-06-30-47,376USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-30222,063USD
At 2023-12-3119,596USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-30636,934USD
At 2023-12-31101,745USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-06-30196,394USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-04-01 to 2024-06-3054,956USD91
2024-01-01 to 2024-06-30114,181USD182
2023-04-01 to 2023-06-3027,806USD91
2023-01-01 to 2023-06-3047,376USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-06-3014,104USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-301,018,519,500shares
At 2023-12-31876,090,000shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-307,486USD
At 2023-12-3119,596USD
At 2023-06-3011,053USD
At 2022-12-31864USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-308,606,040USD
At 2023-12-313,229,489USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-54,800USD91
2024-01-01 to 2024-06-30-114,025USD182
2023-04-01 to 2023-06-30-27,806USD91
2023-01-01 to 2023-06-30-47,376USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-114,025USD91
2024-01-01 to 2024-03-31-65,988USD91
2023-04-01 to 2023-06-30-27,806USD91
2023-01-01 to 2023-03-31-19,570USD90

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-54,800USD91
2024-01-01 to 2024-06-30-114,025USD182
2023-04-01 to 2023-06-30-27,806USD91
2023-01-01 to 2023-06-30-47,376USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-3039,999USD91
2024-01-01 to 2024-06-3061,724USD182
2023-04-01 to 2023-06-3021,001USD91
2023-01-01 to 2023-06-3021,871USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-30196,394USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-3014,104USD182

Inspect the source

Entity
NIKA PHARMACEUTICALS, INC. / CIK 0001145604
Captured
2026-09-20T07:42:29.079Z
SEC response SHA-256
72455d4e19d0f82286a99d0fa349659ab1ab793431c0cac82c5fb18286c89242

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001145604.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))